Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA.
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68. doi: 10.1093/jnci/djy071.
Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, Wang J, Liu Y, Chen P, Wu X, Wen J.
Oncol Rep. 2015 Jun;33(6):2915-23. doi: 10.3892/or.2015.3937. Epub 2015 Apr 28.
Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
McCluggage WG, Vosmikova H, Laco J.
Int J Gynecol Pathol. 2020 Jan;39(1):84-92. doi: 10.1097/PGP.0000000000000573.
Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Kutilin DS, Tsandekova MR, Porkhanova NV.
Bull Exp Biol Med. 2021 Jan;170(3):332-339. doi: 10.1007/s10517-021-05062-1. Epub 2021 Jan 16.
Ovarian Mesonephric-like Adenocarcinoma With Multifocal Microscopic Involvement of the Fimbrial Surface: Potential for Misdiagnosis of Tubal Intraepithelial Metastasis as Serous Tubal Intraepithelial Carcinoma Associated With Ovarian High-grade Serous Carcinoma.
Kim H, Bae GE, Jung YY, Kim HS.
In Vivo. 2021 Nov-Dec;35(6):3613-3622. doi: 10.21873/invivo.12667.
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma.
Li HM, Qiang JW, Xia GL, Zhao SH, Ma FH, Cai SQ, Feng F, Fu AY.
J Ovarian Res. 2015 Apr 30;8:26. doi: 10.1186/s13048-015-0154-2.
High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment.
Vivod G, Merlo S, Kovacevic N.
Curr Oncol. 2024 Apr 2;31(4):1920-1935. doi: 10.3390/curroncol31040144.
High expression of herpesvirus entry mediator (HVEM) in ovarian serous adenocarcinoma tissue.
Fang Y, Ye L, Zhang T, He QZ, Zhu JL.
J BUON. 2017 Jan-Feb;22(1):80-86.
ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.
Kuroda T, Hirohashi Y, Torigoe T, Yasuda K, Takahashi A, Asanuma H, Morita R, Mariya T, Asano T, Mizuuchi M, Saito T, Sato N.
PLoS One. 2013 Jun 6;8(6):e65158. doi: 10.1371/journal.pone.0065158. Print 2013.
CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma.
Miyake T, Ueda Y, Matsuzaki S, Miyatake T, Yoshino K, Fujita M, Nomura T, Enomoto T, Kimura T.
J Cancer Res Clin Oncol. 2011 Apr;137(4):715-22. doi: 10.1007/s00432-010-0930-8. Epub 2010 Jun 23.
